Longer follow-up from an existing trial can answer a new clinical question without becoming an independent new trial. This report focuses on participants who had prediabetes at baseline. Primary report
Study snapshot
The analysis followed 1,032 SURMOUNT-1 participants with obesity and prediabetes through 176 weeks of assigned treatment and 17 weeks off treatment. Tirzepatide groups had greater weight reduction and fewer type 2 diabetes diagnoses than placebo. The off-treatment observation retained a group difference, but some additional diagnoses occurred. Gastrointestinal events remained prominent in the safety findings. Primary report
Our appraisal: prevention claims need a time horizon
A reduction in diagnoses over the observed period is important, but it does not establish permanent lifetime prevention. The time on treatment and the duration after discontinuation should be stated whenever the result is summarized.
The baseline subgroup is equally important. These findings concern people with both obesity and prediabetes, not everyone enrolled in the original study and not every person at possible future risk of diabetes.
Time-to-event measures and simple event proportions describe related but different quantities. A hazard ratio should not be casually relabeled as an absolute risk reduction or as the percentage of all patients who avoided disease. Readers need the comparator risk and follow-up alongside the relative measure.
Because this is extended follow-up, evidence maps should link it to the original SURMOUNT-1 record. Full review should inspect diagnostic criteria, ascertainment after stopping treatment, missing visits, and the controlled endpoint hierarchy. The study does not provide individual eligibility or prescribing guidance.
Frequently asked questions
Did the analysis include the whole original trial population?
It focused on participants with baseline prediabetes and obesity.
Was there observation after treatment ended?
Yes, for 17 weeks.
Does the result establish lifetime prevention?
No.
Is a hazard ratio an absolute risk difference?
No.
Is this independent replication of SURMOUNT-1?
No. It is extended follow-up from that trial.
Should later diagnoses be omitted from the summary?
No. The off-treatment experience is part of the evidence.
What is the key interpretation boundary?
State the population and observation period whenever describing reduced progression to diabetes.